Targeting the Gut Microbiota to Relieve the Symptoms of Irritable Bowel Syndrome

Pathogens

Tamara Daniluk¹  Robert Bucki¹  Urszula Wnorowska¹  Ewelina Piktel¹  Anna Bukłaha²  Tomasz Wollny³  Katarzyna Głuszek⁴  Bonita Durnaś⁴ 

[1] Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, Mickiewicza 2c, 15-222 Białystok, Poland;Department of Microbiological Diagnostics and Infectious Immunology, Medical University of Białystok, Waszyngtona 15a, 15-269 Białystok, Poland;Holy Cross Oncology Center of Kielce, Artwińskiego 3, 25-734 Kielce, Poland;Institute of Medical Science, Collegium Medicum, Jan Kochanowski University in Kielce, 25-734 Kielce, Poland;

关键词: irritable bowel syndrome;    gut microbiome;    small intestinal bacterial overgrowth;    probiotics;    microflora transplantation;   

DOI  :  10.3390/pathogens10121545

来源: DOAJ

【 摘 要 】

Irritable bowel syndrome (IBS) is a common, chronic, functional disorder with a large impact on world population. Its pathophysiology is not completely revealed; however, it is certain that dysregulation of the bidirectional communications between the central nervous system (CNS) and the gut leads to motility disturbances, visceral hypersensitivity, and altered CNS processing characterized by differences in brain structure, connectivity and functional responsiveness. Emerging evidence suggests that gut microbiota exerts a marked influence on the host during health and disease. Gut microbiome disturbances can be also important for development of IBS symptoms and its modulation efficiently contributes to the therapy. In this work, we review the current knowledge about the IBS therapy, the role of gut microbiota in pathogenesis of IBS, and we discuss that its targeting may have significant impact on the effectiveness of IBS therapy.

【 授权许可】

Unknown